Evidence map›Paper›PMID 37558654›Full record

ArticleNature communications2023

Small molecule branched-chain ketoacid dehydrogenase kinase (BDK) inhibitors with opposing effects on BDK protein levels.

Rachel J Roth Flach, Eliza Bollinger, Allan R Reyes, Brigitte Laforest, Bethany L Kormos, Shenping Liu, Matthew R Reese, Luis A Martinez Alsina, Leanne Buzon, Yuan Zhang and 23 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Covalent Reprogramming of Kinase Binders to Modulate Protein Abundance.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Branched-chain amino acid metabolism: Pathophysiological mechanism and therapeutic intervention in metabolic diseases.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025
    Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 1 institution in 1 country.

Rachel J Roth Flach *Pfizer Worldwide Research, Development & Medical, Cambridge, MA, 02139, USA. rachel.rothflach@pfizer.com.ORCID http://orcid.org/0000-0003-2754-828X
Eliza Bollinger *Pfizer Worldwide Research, Development & Medical, Cambridge, MA, 02139, USA.
Allan R ReyesPfizer Worldwide Research, Development & Medical, Cambridge, MA, 02139, USA.
Brigitte LaforestPfizer Worldwide Research, Development & Medical, Cambridge, MA, 02139, USA.
Bethany L KormosPfizer Worldwide Research, Development & Medical, Cambridge, MA, 02139, USA.ORCID http://orcid.org/0000-0003-2298-9369
Shenping LiuPfizer Worldwide Research, Development & Medical, Groton, CT, 06340, USA.ORCID http://orcid.org/0000-0001-9400-3007
Matthew R ReesePfizer Worldwide Research, Development & Medical, Groton, CT, 06340, USA.ORCID http://orcid.org/0000-0002-1066-2652
Luis A Martinez AlsinaPfizer Worldwide Research, Development & Medical, Groton, CT, 06340, USA.
Leanne BuzonPfizer Worldwide Research, Development & Medical, Groton, CT, 06340, USA.
Yuan ZhangPfizer Worldwide Research, Development & Medical, Groton, CT, 06340, USA.
Bruce BechlePfizer Worldwide Research, Development & Medical, Groton, CT, 06340, USA.
Amy RosadoPfizer Worldwide Research, Development & Medical, Groton, CT, 06340, USA.
Parag V SahasrabudhePfizer Worldwide Research, Development & Medical, Groton, CT, 06340, USA.ORCID http://orcid.org/0000-0002-8442-637X
John KnafelsPfizer Worldwide Research, Development & Medical, Groton, CT, 06340, USA.ORCID http://orcid.org/0000-0002-4636-9298
Samit K BhattacharyaPfizer Worldwide Research, Development & Medical, Cambridge, MA, 02139, USA.
Kiyoyuki OmotoPfizer Worldwide Research, Development & Medical, Cambridge, MA, 02139, USA.
John C StansfieldPfizer Worldwide Research, Development & Medical, Cambridge, MA, 02139, USA.
Liam D HurleyPfizer Worldwide Research, Development & Medical, Cambridge, MA, 02139, USA.
LouJin SongPfizer Worldwide Research, Development & Medical, Cambridge, MA, 02139, USA.
Lina LuoPfizer Worldwide Research, Development & Medical, Groton, CT, 06340, USA.ORCID http://orcid.org/0000-0002-1406-7658
Susanne B BreitkopfPfizer Worldwide Research, Development & Medical, Cambridge, MA, 02139, USA.
Mara MonettiPfizer Worldwide Research, Development & Medical, Cambridge, MA, 02139, USA.
Teresa CunioPfizer Worldwide Research, Development & Medical, Cambridge, MA, 02139, USA.ORCID http://orcid.org/0000-0003-2505-5369
Brendan TierneyPfizer Worldwide Research, Development & Medical, Groton, CT, 06340, USA.
Frank J GeolyPfizer Worldwide Research, Development & Medical, Groton, CT, 06340, USA.
Jake DelmorePfizer Worldwide Research, Development & Medical, Cambridge, MA, 02139, USA.
C Parker SiddallPfizer Worldwide Research, Development & Medical, Cambridge, MA, 02139, USA.
Liang XuePfizer Worldwide Research, Development & Medical, Cambridge, MA, 02139, USA.ORCID http://orcid.org/0000-0003-3606-4615
Ka N YipPfizer Worldwide Research, Development & Medical, Cambridge, MA, 02139, USA.
Amit S KalgutkarPfizer Worldwide Research, Development & Medical, Cambridge, MA, 02139, USA.ORCID http://orcid.org/0000-0001-9701-756X
Russell A MillerPfizer Worldwide Research, Development & Medical, Cambridge, MA, 02139, USA.
Bei B ZhangPfizer Worldwide Research, Development & Medical, Cambridge, MA, 02139, USA.
Kevin J FilipskiPfizer Worldwide Research, Development & Medical, Cambridge, MA, 02139, USA. kevin.filipski@pfizer.com.ORCID http://orcid.org/0000-0003-0845-5723
Pfizer (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Branched chain amino acid (BCAA) catabolic impairments have been implicated in several diseases. Branched chain ketoacid dehydrogenase (BCKDH) controls the rate limiting step in BCAA degradation, the activity of which is inhibited by BCKDH kinase (BDK)-mediated phosphorylation. Screening efforts to discover BDK inhibitors led to identification of thiophene PF-07208254, which improved cardiometabolic endpoints in mice. Structure-activity relationship studies led to identification of a thiazole series of BDK inhibitors; however, these inhibitors did not improve metabolism in mice upon chronic administration. While the thiophenes demonstrated sustained branched chain ketoacid (BCKA) lowering and reduced BDK protein levels, the thiazoles increased BCKAs and BDK protein levels. Thiazoles increased BDK proximity to BCKDH-E2, whereas thiophenes reduced BDK proximity to BCKDH-E2, which may promote BDK degradation. Thus, we describe two BDK inhibitor series that possess differing attributes regarding BDK degradation or stabilization and provide a mechanistic understanding of the desirable features of an effective BDK inhibitor.

Indexed as

Amino Acids, Branched-ChainThiophenesAnimalsMiceOxidoreductasesPhosphorylationAmino Acids, Branched-ChainOxidoreductasesThiophenes

Identifiers

PMID37558654
PMCPMC10412597
OpenAlexW4385693593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.